MARCH2 promotes endocytosis and lysosomal sorting of carvedilol-bound β2-adrenergic receptors

Journal of Cell Biology

Volumn 199, Issue 5, 2012, Pages 817-830

  Han, Sang oh ^a   Xiao, Kunhong ^a   Kim, Jihee ^a   Wu, Jiao Hui ^a   Wisler, James W ^a   Nakamura, Nobuhiro ^b   Freedman, Neil J ^a   Shenoy, Sudha K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CARVEDILOL; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E3 MARCH2; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG; USP20 PROTEIN; USP33 PROTEIN;

ARTICLE; CELL MIGRATION; CELL SELECTION; CONTROLLED STUDY; DISSOCIATION; ENDOCYTOSIS; HUMAN; HUMAN CELL; INTERNALIZATION; LIQUID CHROMATOGRAPHY; LYSOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SMOOTH MUSCLE FIBER; TANDEM MASS SPECTROMETRY; UBIQUITINATION; VASCULAR SMOOTH MUSCLE CELL;

EID: 84871997357     PISSN: 00219525     EISSN: 15408140     Source Type: Journal    
DOI: 10.1083/jcb.201208192     Document Type: Article

References (72)

1. Ahn, S., S. Maudsley, L.M. Luttrell, R.J. Lefkowitz, and Y. Daaka. 1999. Src-mediated tyrosine phosphorylation of dynamin is required for beta2-adrenergic receptor internalization and mitogen-activated protein kinase signaling. J. Biol. Chem. 274:1185-1188. http://dx.doi.org/10.1074/jbc.274.3.1185
2. Becuwe, M., N. Vieira, D. Lara, J. Gomes-Rezende, C. Soares-Cunha, M. Casal, R. Haguenauer-Tsapis, O. Vincent, S. Paiva, and S. Léon. 2012. A molecular switch on an arrestin-like protein relays glucose signaling to transporter endocytosis. J. Cell Biol. 196:247-259. http://dx.doi.org/10.1083/jcb.201109113
3. Berthouze, M., V. Venkataramanan, Y. Li, and S.K. Shenoy. 2009. The deubiquitinases USP33 and USP20 coordinate beta2 adrenergic receptor recycling and resensitization. EMBO J. 28:1684-1696. http://dx.doi.org/10.1038/emboj.2009.128
4. Bristow, M.R. 2000. Mechanistic and clinical rationales for using beta-blockers in heart failure. J. Card. Fail. 6:8-14.
5. Cadwell, K., and L. Coscoy. 2005. Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase. Science. 309:127-130. http://dx.doi.org/10.1126/science.1110340
6. Cao, Z., A. Huett, P. Kuballa, C. Giallourakis, and R.J. Xavier. 2008. DLG1 is an anchor for the E3 ligase MARCH2 at sites of cell-cell contact. Cell. Signal. 20:73-82. http://dx.doi.org/10.1016/j.cellsig.2007.08.019
7. Cohn, J.N., D.G. Archibald, S. Ziesche, J.A. Franciosa, W.E. Harston, F.E. Tristani, W.B. Dunkman, W. Jacobs, G.S. Francis, K.H. Flohr, et al. 1986. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. 314:1547-1552. http://dx.doi.org/10.1056/NEJM198606123142404
8. DeWire, S.M., and J.D. Violin. 2011. Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ. Res. 109:205-216. http://dx.doi.org/10.1161/CIRCRESAHA.110.231308
9. DeWire, S.M., S. Ahn, R.J. Lefkowitz, and S.K. Shenoy. 2007. Beta-arrestins and cell signaling. Annu. Rev. Physiol. 69:483-510. http://dx.doi.org/10.1146/annurev.physiol.69.022405.154749
10. Domanski, M.J., H. Krause-Steinrauf, B.M. Massie, P. Deedwania, D. Follmann, D. Kovar, D. Murray, R. Oren, Y. Rosenberg, J. Young, et al. BEST Investigators. 2003. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J. Card. Fail. 9:354-363. http://dx.doi.org/10.1054/S1071-9164(03)00133-7
11. Eyster, C.A., N.B. Cole, S. Petersen, K. Viswanathan, K. Früh, and J.G. Donaldson. 2011. MARCH ubiquitin ligases alter the itinerary of clathrin- independent cargo from recycling to degradation. Mol. Biol. Cell. 22:3218-3230. http://dx.doi.org/10.1091/mbc.E10-11-0874
12. Feuerstein, G.Z., S.A. Hamburger, E.F. Smith III, A. Bril, and R.R. Ruffolo Jr. 1992. Myocardial protection with carvedilol. J. Cardiovasc. Pharmacol. 19(Suppl 1):S138-S141. http://dx.doi.org/10.1097/00005344-199219001-00027
13. Flesch, M., S. Ettelbrück, S. Rosenkranz, C. Maack, B. Cremers, K.D. Schlüter, O. Zolk, and M. Böhm. 2001. Differential effects of carvedilol and metoprolol on isoprenaline-induced changes in beta-adrenoceptor density and systolic function in rat cardiac myocytes. Cardiovasc. Res. 49:371-380. http://dx.doi.org/10.1016/S0008-6363(00)00277-7
14. Fujimuro, M., and H. Yokosawa. 2005. Production of antipolyubiquitin monoclonal antibodies and their use for characterization and isolation of polyubiquitinated proteins. Methods Enzymol. 399:75-86. http://dx.doi.org/10.1016/S0076-6879(05)99006-X
15. Gagnon, A.W., L. Kallal, and J.L. Benovic. 1998. Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the beta2-adrenergic receptor. J. Biol. Chem. 273:6976-6981. http://dx.doi.org/10.1074/jbc.273.12.6976
16. Galandrin, S., G. Oligny-Longpré, and M. Bouvier. 2007. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol. Sci. 28:423-430. http://dx.doi.org/10.1016/j.tips.2007.06.005
17. Gilbert, E.M., W.T. Abraham, S. Olsen, B. Hattler, M. White, P. Mealy, P. Larrabee, and M.R. Bristow. 1996. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 94:2817-2825. http://dx.doi.org/10.1161/01.CIR.94.11.2817
18. Haas, W., B.K. Faherty, S.A. Gerber, J.E. Elias, S.A. Beausoleil, C.E. Bakalarski, X. Li, J. Villén, and S.P. Gygi. 2006. Optimization and use of peptide mass measurement accuracy in shotgun proteomics. Mol. Cell. Proteomics. 5:1326-1337. http://dx.doi.org/10.1074/mcp.M500339-MCP200
19. Haigler, H.T., F.R. Maxfield, M.C. Willingham, and I. Pastan. 1980. Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. J. Biol. Chem. 255:1239-1241.
20. Hamburger, S.A., F.C. Barone, G.Z. Feuerstein, and R.R. Ruffolo Jr. 1991. Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology. 43:113-120. http://dx.doi.org/10.1159/000138836
21. Heilbrunn, S.M., P. Shah, M.R. Bristow, H.A. Valantine, R. Ginsburg, and M.B. Fowler. 1989. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 79 :483-490. http://dx.doi.org/10.1161/01.CIR.79.3.483
22. Herr, R.A., J. Harris, S. Fang, X. Wang, and T.H. Hansen. 2009. Role of the RING-CH domain of viral ligase mK3 in ubiquitination of non-lysine and lysine MHC I residues. Traffic. 10:1301-1317. http://dx.doi.org/10.1111/j.1600-0854.2009.00946.x
23. Hunt, S.A., W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, T.G. Ganiats, M. Jessup, M.A. Konstam, D.M. Mancini, K. Michl, et al; American College of Cardiology Foundation; American Heart Association. 2009. 2009 focused update incorporated into the ACC/ AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on PracticeGuidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53:e1-e90. http://dx.doi.org/10.1016/j.jacc.2008.11.013
24. Jabbour, A., P.S. Macdonald, A.M. Keogh, E. Kotlyar, S. Mellemkjaer, C.F. Coleman, M. Elsik, H. Krum, and C.S. Hayward. 2010. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J. Am. Coll. Cardiol. 55:1780-1787. http://dx.doi.org/10.1016/j.jacc.2010.01.024
25. Joazeiro, C.A., and A.M. Weissman. 2000. RING finger proteins: mediators of ubiquitin ligase activity. Cell. 102:549-552. http://dx.doi.org/10.1016/S0092-8674(00)00077-5
26. Keys, J.R., R.H. Zhou, D.M. Harris, C.A. Druckman, and A.D. Eckhart. 2005. Vascular smooth muscle overexpression of G protein-coupled receptor kinase 5 elevates blood pressure, which segregates with sex and is dependent on Gi-mediated signaling. Circulation. 112:1145-1153. http://dx.doi.org/10.1161/CIRCULATIONAHA.104.531657
27. Kim, I.M., D.G. Tilley, J. Chen, N.C. Salazar, E.J. Whalen, J.D. Violin, and H.A. Rockman. 2008a. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc. Natl. Acad. Sci. USA. 105:14555-14560. http://dx.doi.org/10.1073/pnas.0804745105
28. Kim, J., L. Zhang, K. Peppel, J.H. Wu, D.A. Zidar, L. Brian, S.M. DeWire, S.T. Exum, R.J. Lefkowitz, and N.J. Freedman. 2008b. Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ. Res. 103:70-79. http://dx.doi.org/10.1161/CIRCRESAHA.108.172338
29. Kindermann, M., C. Maack, S. Schaller, N. Finkler, K.I. Schmidt, S. Läer, H. Wuttke, H.J. Schäfers, and M. Böhm. 2004. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation. 109:3182-3190. http://dx.doi.org/10.1161/01.CIR.0000130849.08704.24
30. Kohout, T.A., F.S. Lin, S.J. Perry, D.A. Conner, and R.J. Lefkowitz. 2001. beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc. Natl. Acad. Sci. USA. 98:1601-1606.
31. Lal, A., S.R. Haynes, and M. Gorospe. 2005. Clean Western blot signals from immunoprecipitated samples. Mol. Cell. Probes. 19:385-388. http://dx.doi.org/10.1016/j.mcp.2005.06.007
32. Lasagna, L. 2000. Diuretics vs alpha-blockers for treatment of hypertension: lessons from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA. 283:2013-2014. http://dx.doi.org/10.1001/jama.283.15.2013
33. Liang, W., and P.H. Fishman. 2004. Resistance of the human beta1-adrenergic receptor to agonist-induced ubiquitination: a mechanism for impaired receptor degradation. J. Biol. Chem. 279:46882-46889. http://dx.doi.org/10.1074/jbc.M406501200
34. Liang, W., Q. Hoang, R.B. Clark, and P.H. Fishman. 2008. Accelerated dephosphorylation of the beta2-adrenergic receptor by mutation of the C-terminal lysines: effects on ubiquitination, intracellular trafficking, and degradation. Biochemistry. 47:11750-11762. http://dx.doi.org/10 .1021/bi800219q
35. Lin, C.H., J.A. MacGurn, T. Chu, C.J. Stefan, and S.D. Emr. 2008. Arrestinrelated ubiquitin-ligase adaptors regulate endocytosis and protein turnover at the cell surface. Cell. 135:714-725. http://dx.doi.org/10.1016/j.cell.2008.09.025
36. Louis, A., J.G. Cleland, S. Crabbe, S. Ford, S. Thackray, T. Houghton, and A. Clark. 2001. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur. J. Heart Fail. 3:381-387. http://dx.doi.org/10.1016/S1388-9842(01)00149-0
37. Macia, E., M. Ehrlich, R. Massol, E. Boucrot, C. Brunner, and T. Kirchhausen. 2006. Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell. 10: 839-850. http://dx.doi.org/10.1016/j.devcel.2006.04.002
38. Marchese, A., and J.L. Benovic. 2001. Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. J. Biol. Chem. 276:45509-45512. http://dx.doi.org/10.1074/jbc.C100527200
39. Moore, C.A., S.K. Milano, and J.L. Benovic. 2007. Regulation of receptor trafficking by GRKs and arrestins. Annu. Rev. Physiol. 69:451-482. http://dx.doi.org/10.1146/annurev.physiol.69.022405.154712
40. Nabhan, J.F., H. Pan, and Q. Lu. 2010. Arrestin domain-containing protein 3 recruits the NEDD4 E3 ligase to mediate ubiquitination of the beta2-adrenergic receptor. EMBO Rep. 11:605-611. http://dx.doi.org/ 10.1038/embor.2010.80
41. Nakamura, N., H. Fukuda, A. Kato, and S. Hirose. 2005. MARCH-II is a syntaxin-6-binding protein involved in endosomal trafficking. Mol. Biol. Cell. 16:1696-1710. http://dx.doi.org/10.1091/mbc.E04-03-0216
42. Nandi, P.K., P.P. Van Jaarsveld, R.E. Lippoldt, and H. Edelhoch. 1981. Effect of basic compounds on the polymerization of clathrin. Biochemistry. 20:6706-6710. http://dx.doi.org/10.1021/bi00526a028
43. Nathan, J.A., and P.J. Lehner. 2009. The trafficking and regulation of membrane receptors by the RING-CH ubiquitin E3 ligases. Exp. Cell Res. 315:1593-1600. http://dx.doi.org/10.1016/j.yexcr.2008.10.026
44. Neves, S.R., P.T. Ram, and R. Iyengar. 2002. G protein pathways. Science. 296:1636-1639. http://dx.doi.org/10.1126/science.1071550
45. Nikko, E., J.A. Sullivan, and H.R. Pelham. 2008. Arrestin-like proteins mediate ubiquitination and endocytosis of the yeast metal transporter Smf1. EMBO Rep. 9:1216-1221. http://dx.doi.org/10.1038/embor.2008.199
46. Nikolaev, V.O., A. Moshkov, A.R. Lyon, M. Miragoli, P. Novak, H. Paur, M.J. Lohse, Y.E. Korchev, S.E. Harding, and J. Gorelik. 2010. Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science. 327:1653-1657. http://dx.doi.org/10.1126/science.1185988
47. Nobles, K.N., K. Xiao, S. Ahn, A.K. Shukla, C.M. Lam, S. Rajagopal, R.T. Strachan, T.Y. Huang, E.A. Bressler, M.R. Hara, et al. 2011. Distinct phosphorylation sites on the β(2)-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin. Sci. Signal. 4:ra51. http://dx.doi.org/10.1126/scisignal.2001707
48. Ohmura-Hoshino, M., E. Goto, Y. Matsuki, M. Aoki, M. Mito, M. Uematsu, H. Hotta, and S. Ishido. 2006. A novel family of membrane-bound E3 ubiquitin ligases. J. Biochem. 140:147-154. http://dx.doi.org/10.1093/jb/mvj160
49. Phonphok, Y., and K.S. Rosenthal. 1991. Stabilization of clathrin coated vesicles by amantadine, tromantadine and other hydrophobic amines. FEBS Lett. 281:188-190. http://dx.doi.org/10.1016/0014-5793(91)80390-O
50. Pierce, K.L., S. Maudsley, Y. Daaka, L.M. Luttrell, and R.J. Lefkowitz. 2000. Role of endocytosis in the activation of the extracellular signal-regulated kinase cascade by sequestering and nonsequestering G protein-coupled receptors. Proc. Natl. Acad. Sci. USA. 97:1489-1494. http://dx.doi.org/10.1073/pnas.97.4.1489
51. Polo, S., and P.P. Di Fiore. 2008. Finding the right partner: science or ART? Cell. 135:590-592. http://dx.doi.org/10.1016/j.cell.2008.10.032
52. Reiter, E., and R.J. Lefkowitz. 2006. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17:159-165. http://dx.doi.org/10.1016/j.tem.2006.03.008
53. Ritter, S.L., and R.A. Hall. 2009. Fine-tuning of GPCR activity by receptorinteracting proteins. Nat. Rev. Mol. Cell Biol. 10:819-830. http://dx.doi.org/10.1038/nrm2803
54. Rohrer, D.K., K.H. Desai, J.R. Jasper, M.E. Stevens, D.P. Regula Jr., G.S. Barsh, D. Bernstein, and B.K. Kobilka. 1996. Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. Proc. Natl. Acad. Sci. USA. 93:7375-7380. http://dx.doi .org/10.1073/pnas.93.14.7375
55. Rosenbaum, D.M., S.G. Rasmussen, and B.K. Kobilka. 2009. The structure and function of G-protein-coupled receptors. Nature. 459:356-363. http://dx.doi.org/10.1038/nature08144
56. Ruffolo, R.R. Jr., and G.Z. Feuerstein. 1997. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc. Drugs Ther. 11(Suppl 1):247-256. http://dx.doi.org/10.1023/A:1007735729121
57. Ruffolo, R.R. Jr., M. Gellai, J.P. Hieble, R.N. Willette, and A.J. Nichols. 1990. The pharmacology of carvedilol. Eur. J. Clin. Pharmacol. 38:S82-S88. http://dx.doi.org/10.1007/BF01409471
58. Shenoy, S.K. 2007. Seven-transmembrane receptors and ubiquitination. Circ. Res. 100:1142-1154. http://dx.doi.org/10.1161/01.RES.0000261939.88744.5a
59. Shenoy, S.K. 2011. β-arrestin-biased signaling by the β-adrenergic receptors. Curr. Top. Membr. 67:51-78. http://dx.doi.org/10.1016/B978-0-12-384921-2.00003-3
60. Shenoy, S.K., and R.J. Lefkowitz. 2003. Trafficking patterns of beta-arrestin and G protein-coupled receptors determined by the kinetics of betaarrestin deubiquitination. J. Biol. Chem. 278:14498-14506. http://dx.doi.org/10.1074/jbc.M209626200
61. Shenoy, S.K., and R.J. Lefkowitz. 2011. β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci. 32:521-533. http://dx.doi.org/10.1016/j.tips.2011.05.002
62. Shenoy, S.K., P.H. McDonald, T.A. Kohout, and R.J. Lefkowitz. 2001. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science. 294:1307-1313. http://dx.doi .org/10.1126/science.1063866
63. Shenoy, S.K., L.S. Barak, K. Xiao, S. Ahn, M. Berthouze, A.K. Shukla, L.M. Luttrell, and R.J. Lefkowitz. 2007. Ubiquitination of beta-arrestin links seven-transmembrane receptor endocytosis and ERK activation. J. Biol. Chem. 282:29549-29562. http://dx.doi.org/10.1074/jbc.M700852200
64. Shenoy, S.K., K. Xiao, V. Venkataramanan, P.M. Snyder, N.J. Freedman, and A.M. Weissman. 2008. Nedd4 mediates agonist-dependent ubiquitination, lysosomal targeting, and degradation of the beta2-adrenergic receptor. J. Biol. Chem. 283:22166-22176. http://dx.doi.org/10.1074/jbc.M709668200
65. Vanderhoff, B.T., H.M. Ruppel, and P.B. Amsterdam. 1998. Carvedilol: the new role of beta blockers in congestive heart failure. Am. Fam. Physician. 58:1627-1634: 1641-1642.
66. Wang, X., R.A. Herr, and T. Hansen. 2008. Viral and cellular MARCH ubiquitin ligases and cancer. Semin. Cancer Biol. 18:441-450. http://dx.doi.org/10.1016/j.semcancer.2008.09.002
67. Wisler, J.W., S.M. DeWire, E.J. Whalen, J.D. Violin, M.T. Drake, S. Ahn, S.K. Shenoy, and R.J. Lefkowitz. 2007. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc. Natl. Acad. Sci. USA. 104:16657-16662. http://dx.doi.org/10.1073/pnas.0707936104
68. Xiao, K., and S.K. Shenoy. 2011. Beta2-adrenergic receptor lysosomal trafficking is regulated by ubiquitination of lysyl residues in two distinct receptor domains. J. Biol. Chem. 286:12785-12795. http://dx.doi.org/10.1074/jbc.M110.203091
69. Xiao, K., D.B. McClatchy, A.K. Shukla, Y. Zhao, M. Chen, S.K. Shenoy, J.R. Yates III, and R.J. Lefkowitz. 2007. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc. Natl. Acad. Sci. USA. 104:12011-12016. http://dx.doi.org/10.1073/pnas.0704849104
70. Xiao, R.P., W. Zhu, M. Zheng, K. Chakir, R. Bond, E.G. Lakatta, and H. Cheng. 2004. Subtype-specific beta-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol. Sci. 25:358-365. http://dx.doi.org/10.1016/j.tips.2004.05.007
71. Yamada, S., T. Ohkura, S. Uchida, K. Inabe, Y. Iwatani, R. Kimura, T. Hoshino, and T. Kaburagi. 1996. A sustained increase in beta-adrenoceptors during long-term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy. Life Sci. 58:1737-1744. http://dx.doi.org/10.1016/0024-3205(96)00155-5
72. Zhang, J., S.S. Ferguson, L.S. Barak, L. Ménard, and M.G. Caron. 1996. Dynamin and beta-arrestin reveal distinct mechanisms for G proteincoupled receptor internalization. J. Biol. Chem. 271:18302-18305. http://dx.doi.org/10.1074/jbc.271.31.18302